CTOs on the Move

Oxford Pharmaceutical Resources

www.oxfordpharm.com

 
Oxford Pharmaceutical Resources is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Acara MedSpas

Acara MedSpas is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

E-Way International

E-Way International is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Analytical Industries

Analytical Industries is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

O2 Concepts

O2 Concepts has reimagined non-delivery, stepping forward as the first manufacturer to create a smart POC integrated over the Verizon Network that benefits dealers and patients alike. Dynamic Network Analysis (DNA) allows oxygen providers to monitor all devices remotely for location, usage and performance, as well as troubleshoot to prevent any unnecessary dispatches. DNA Technology™ serves as an additional upgrade to 24/7 reliability and the Oxlife Independence`s standard 5 year warranty. O2 Concepts is privately held with factory operations in Newtown, CT and all products are proudly made in the USA.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.